Trials / Completed
CompletedNCT02462486
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 949 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abicipar Pegol | Abicipar pegol intravitreal injection. |
| DRUG | Ranibizumab | Ranibizumab intravitreal injection. |
| OTHER | Sham Procedure | Sham injection. |
Timeline
- Start date
- 2015-06-25
- Primary completion
- 2018-04-12
- Completion
- 2019-06-06
- First posted
- 2015-06-04
- Last updated
- 2020-07-30
- Results posted
- 2020-07-30
Locations
187 sites across 16 countries: United States, Australia, Brazil, Canada, Denmark, Hungary, Italy, Japan, Netherlands, Peru, Poland, Russia, South Africa, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02462486. Inclusion in this directory is not an endorsement.